← Leaderboards
Prashanthi Vemuri
Mayo Clinic Rochester
$20,262,102
Attributed
$36,807,626
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10.2M · FY2011–25$20M$15M$10M$5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,807,626 · 10
By mechanism
R01$14,535,728 · 4
U01$11,991,901 · 1
UF1$6,100,999 · 1
RF1$2,360,353 · 1
P50$901,135 · 1
R00$739,530 · 1
Top collaborators
- Jonathan Graff-Radford7 shared
- Ronald C Petersen6 shared
- Wolfgang Singer5 shared
- Clifford Jack4 shared
- Michelle M Mielke3 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Hilal Maradit Kremers$11,722,206
- Wolfgang Singer$6,707,804
- Jennifer Lynn St Sauver$8,545,756
- Howard J Rosen$46,265,858
- Andrew D Rule$13,956,498
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposImageDementiaCognitiveMagnetic Resonance ImagingS DiseaseAgingAmyloidPositron-Emission TomographyPopulation BasedCognitionCohortImpaired CognitionClinicBaseCerebrovascular DisordersNerve DegenerationBiological MarkersParticipantSamplingSuccessPathologyTau ProteinsImaging Biomarker
Grant awards (37)
Synucleinopathies â Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$765,340
R01 · FY2025 · NS
Investigating Resistance and Resilience Mechanisms in Alzheimerâs Disease$764,047
R01 · FY2025 · AG · contact PI
"What is N?" Towards operationalizing neurodegeneration in Alzheimer's and related dementias$727,449
R01 · FY2025 · AG
"What is N?" Towards operationalizing neurodegeneration in Alzheimer's and related dementias$793,724
R01 · FY2024 · AG
Investigating Resistance and Resilience Mechanisms in Alzheimerâs Disease$779,639
R01 · FY2024 · AG · contact PI
Synucleinopathies â Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$765,340
R01 · FY2024 · NS
Alzheimers Disease Patient Registry$3,907,919
U01 · FY2023 · AG
MarkVCID Validation in the General Community$3,646,845
UF1 · FY2023 · NS
Investigating Resistance and Resilience Mechanisms in Alzheimerâs Disease$810,339
R01 · FY2023 · AG · contact PI
Synucleinopathies â Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$765,340
R01 · FY2023 · NS
Alzheimers Disease Patient Registry (Administrative Supplement)$301,515
U01 · FY2023 · AG
Alzheimers Disease Patient Registry$3,907,919
U01 · FY2022 · AG
Synucleinopathies â Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$765,405
R01 · FY2022 · NS
Alzheimers Disease Patient Registry$3,874,548
U01 · FY2021 · AG
MarkVCID Validation in the General Community$2,454,154
UF1 · FY2021 · NS
"What is N?" Towards operationalizing neurodegeneration in Alzheimer's and related dementias$2,360,353
RF1 · FY2021 · AG
Exceptional Aging: Identifying Modifiers of Alzheimer's Disease Trajectories$777,951
R01 · FY2021 · AG · contact PI
Synucleinopathies â Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$765,405
R01 · FY2021 · NS
Exceptional Aging: Identifying Modifiers of Alzheimer's Disease Trajectories$777,951
R01 · FY2020 · AG · contact PI
Development, Validation, and Application of an Imaging based CVD Scale$613,328
R01 · FY2020 · NS · contact PI
Exceptional Aging: Identifying Modifiers of Alzheimer's Disease Trajectories$774,901
R01 · FY2019 · AG · contact PI
Development, Validation, and Application of an Imaging based CVD Scale$619,459
R01 · FY2019 · NS · contact PI
Exceptional Aging: Identifying Modifiers of Alzheimer's Disease Trajectories$781,451
R01 · FY2018 · AG · contact PI
Development, Validation, and Application of an Imaging based CVD Scale$619,807
R01 · FY2018 · NS · contact PI
Project 1$184,384
P50 · FY2018 · AG · contact PI
Exceptional Aging: Identifying Modifiers of Alzheimer's Disease Trajectories$791,656
R01 · FY2017 · AG · contact PI
Development, Validation, and Application of an Imaging based CVD Scale$538,598
R01 · FY2017 · NS · contact PI
Project 1$181,526
P50 · FY2017 · AG · contact PI
Development, Validation, and Application of an Imaging based CVD Scale$538,598
R01 · FY2016 · NS · contact PI
Project 1$150,124
P50 · FY2016 · AG · contact PI
HOW DOES RESERVE MODIFY LINKS BETWEEN COGNITION & IMAGING INDICES OF AD PATHOLOGY$241,530
R00 · FY2015 · AG · contact PI
Project 1$190,132
P50 · FY2015 · AG · contact PI
HOW DOES RESERVE MODIFY LINKS BETWEEN COGNITION & IMAGING INDICES OF AD PATHOLOGY$249,000
R00 · FY2014 · AG · contact PI
Project 1$194,969
P50 · FY2014 · AG · contact PI
HOW DOES RESERVE MODIFY LINKS BETWEEN COGNITION & IMAGING INDICES OF AD PATHOLOGY$249,000
R00 · FY2013 · AG · contact PI
HOW DOES RESERVE MODIFY LINKS BETWEEN COGNITION & IMAGING INDICES OF AD PATHOLOGY$87,980
K99 · FY2012 · AG · contact PI
HOW DOES RESERVE MODIFY LINKS BETWEEN COGNITION & IMAGING INDICES OF AD PATHOLOGY$90,000
K99 · FY2011 · AG · contact PI